- Email: [email protected]
4833130 Treatment of human viral infections
PATENT ABSTRACTS
4833085 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN COLON FIBROBLAST-DERIVED T-PA
599
pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the Y-mono, di- and triphosphate of 3’-axido-3’-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Jon P Schaumann, Jitka V Olander, Nicholaos K Harakas, Joseph Feder assigned to Monsanto Company A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.
4833166 GROWTH HORMONE RELEASING HORMONE COMPLEMENTARY PEPTIDES Clark E Grosvenor,
4833127 NOVEL CSF AND METHOD FOR OBTAINING THE SAME Masayoshi Ono, Hitosh Nomura, Saitama, Japan assigned to Chugai Seiyaku Kabushiki Kaisha A novel colony stimulating factor (CSF) that has the ability to promote the differentiation and proliferation of human bone marrow cells to neutrophiles, and a method for obtaining the same are disclosed. This CSF is produced from a novel cell line which has been established from tumor cells in patients with oral cancer. This CSF has the potential for use only as a curative for leukopenia but also as a reagent for clinical testing and research studies.
4833130 TREATMENT OF HUMAN VIRAL INFECTIONS Janet L Rideout, David Barry, Sandra Lehrman, Clair Martha H St, Phillip A Furman assigned to Burroughs Wellcome Co Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the com3’-azido-3’-deoxythymidine or a pound
Balint Kacsoh
The present invention provides synthetic peptides and fragments and analogs thereof complementary to growth hormone releasing hormone, and antibodies raised against such peptides. The present invention also includes methods of using such peptides and antibodies.
4834974 IMMUNOLOGICALLY ACTIVE WHEY FRACTION AND RECOVERY PROCESS Gerald H Stott, David 0 Lucas assigned to Protein Technologies Inc A dry, immunologically active filtered product is produced through the controlled one or two stage ultrafiltration of liquid whey containing immunologically active immunoglobulin (Ig). When a predetermined quantity of the filtered product with an active Ig concentration of at least about seven percent of total solids is fed to newborn calves, the product functions as a substitute for natural colostrum, providing both temporary passive immunity as well as initiation of the active immune system of the animal. Disease resistance and growth rate in animals including humans is enhanced by oral administration of the filtered product. The immunological properties of the filtered product result from the presence of substantially enhanced concentrations of active Ig as well as other immunologically active whey components in comparison to the immunologically ineffective concentrations of these materials in the liquid whey ultrafiltration feedstock.
4833085 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN COLON FIBROBLAST-DERIVED T-PA
599
pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the Y-mono, di- and triphosphate of 3’-axido-3’-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Jon P Schaumann, Jitka V Olander, Nicholaos K Harakas, Joseph Feder assigned to Monsanto Company A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.
4833166 GROWTH HORMONE RELEASING HORMONE COMPLEMENTARY PEPTIDES Clark E Grosvenor,
4833127 NOVEL CSF AND METHOD FOR OBTAINING THE SAME Masayoshi Ono, Hitosh Nomura, Saitama, Japan assigned to Chugai Seiyaku Kabushiki Kaisha A novel colony stimulating factor (CSF) that has the ability to promote the differentiation and proliferation of human bone marrow cells to neutrophiles, and a method for obtaining the same are disclosed. This CSF is produced from a novel cell line which has been established from tumor cells in patients with oral cancer. This CSF has the potential for use only as a curative for leukopenia but also as a reagent for clinical testing and research studies.
4833130 TREATMENT OF HUMAN VIRAL INFECTIONS Janet L Rideout, David Barry, Sandra Lehrman, Clair Martha H St, Phillip A Furman assigned to Burroughs Wellcome Co Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the com3’-azido-3’-deoxythymidine or a pound
Balint Kacsoh
The present invention provides synthetic peptides and fragments and analogs thereof complementary to growth hormone releasing hormone, and antibodies raised against such peptides. The present invention also includes methods of using such peptides and antibodies.
4834974 IMMUNOLOGICALLY ACTIVE WHEY FRACTION AND RECOVERY PROCESS Gerald H Stott, David 0 Lucas assigned to Protein Technologies Inc A dry, immunologically active filtered product is produced through the controlled one or two stage ultrafiltration of liquid whey containing immunologically active immunoglobulin (Ig). When a predetermined quantity of the filtered product with an active Ig concentration of at least about seven percent of total solids is fed to newborn calves, the product functions as a substitute for natural colostrum, providing both temporary passive immunity as well as initiation of the active immune system of the animal. Disease resistance and growth rate in animals including humans is enhanced by oral administration of the filtered product. The immunological properties of the filtered product result from the presence of substantially enhanced concentrations of active Ig as well as other immunologically active whey components in comparison to the immunologically ineffective concentrations of these materials in the liquid whey ultrafiltration feedstock.